BCR and chronic myelogenous leukemia, BCR-ABL1 positive: This study firstly proposed a better, more precise early prognosis index at 3 months, especially for the CML-CP patients with BCR-ABL1IS >10%, which consequently guide the treatment switching in time to improve the level of molecular response and quality of life of patients.